European Commission Approves Merck’s Capvaxive Vaccine for Adults
European Commission Approves Merck’s Capvaxive Vaccine for Adults
Table of Contents
Approval clears the way for wider use of the pneumococcal vaccine in Europe.
The European Commission has approved Merck’s Capvaxive vaccine for use in adults. This decision allows for the vaccine to be administered across member states of the European Union.
Capvaxive is a pneumococcal 21-valent conjugate vaccine designed to protect against 21 serotypes of the bacteria that cause pneumococcal disease. According to Merck, individuals experiencing side effects or with product quality complaints can call 1-800-672-6372 to report them.
In the United States, Merck has set the price of Capvaxive at $287 per dose for immunization.
The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet on June 27 to discuss recommendations regarding the vaccine.
More information, including frequently asked questions about Capvaxive and possible side effects, can be found at Capvaxive.com.
Capvaxive: Your Questions Answered
What is Capvaxive?
Capvaxive is a pneumococcal 21-valent conjugate vaccine, designed to protect adults against invasive pneumococcal disease and pneumonia caused by certain types of Streptococcus pneumoniae bacteria (pneumococcus). This vaccine is for individuals 18 years of age and older.
What Kind of Protection Does Capvaxive Offer?
Capvaxive protects against 21 serotypes of the bacteria that cause pneumococcal disease.
Were is Capvaxive available?
The European Commission has approved the vaccine,allowing it to be administered across European Union member states. Additionally, Capvaxive is available in the United States.
How Much Does Capvaxive Cost?
In the United States, the listed price for a single dose of Capvaxive is $287.
Where Can I Find More Facts About Capvaxive?
You can find frequently asked questions and other information on the official Capvaxive website.
What Should I do if I Experience Side Effects or Have Complaints?
If you experience any side effects or have product quality complaints, you can contact Merck at 1-800-672-6372 to report them.
Key facts About capvaxive
| Feature | Details |
| —————————– | —————————————————————————– |
| Type of Vaccine | Pneumococcal 21-valent conjugate vaccine |
| Target Population | Adults aged 18 years and older |
| Protection Against | 21 serotypes of Streptococcus pneumoniae (pneumococcus) |
| Availability | european Union member states, United States |
| Report Side Effects |Call 1-800-672-6372 |
| Price in US | $287 per dose |